AR058624A1 - PIRIMIDINE DERIVATIVES AS INHIBITORS OF PIRIMIDIN QUINASA SUBSTITUTES. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. - Google Patents
PIRIMIDINE DERIVATIVES AS INHIBITORS OF PIRIMIDIN QUINASA SUBSTITUTES. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS.Info
- Publication number
- AR058624A1 AR058624A1 ARP060105731A ARP060105731A AR058624A1 AR 058624 A1 AR058624 A1 AR 058624A1 AR P060105731 A ARP060105731 A AR P060105731A AR P060105731 A ARP060105731 A AR P060105731A AR 058624 A1 AR058624 A1 AR 058624A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- aryl
- amino
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Su síntesis y uso para tratar, prevenir o mejorar una enfermedad, trastorno o alteracion cronica o aguda intermediada por proteinquinasas. Reivindicacion 1: Un compuesto de formula (1) y formas de éste, donde L está seleccionado entre un enlace, alquilo C1-6 o halo-alquilo C1-6; Ar está seleccionado entre arilo, heteroarilo, heterociclilo benzofusionado o cicloalquilo C3-12 benzofusionado, donde la porcion de anillo benceno del sistema de anillo benzofusionado está unida a la variable L; RA está seleccionado entre C=N-O-R1 o ciano; R1 está seleccionado entre H, alquilo C1-8, alquenilo C1-8, alcoxi C1-8, alcoxi C1-8-alquilo C1-8, hidroxi-alquilo C1-8, hidroxi-alcoxi C1-8, amino-alquilo C1-8, alquilo C1-8-amino-alquilo C1-8, alcoxi C1-8- alquilo C1-8-amino-alquilo C1-8, alquilo C1-8-sulfonil-alquilo C1-8, alquilo C1-8-sulfoniloxi-alquilo C1-8, arilo, aril-alquilo C1-8, ariloxi-alquilo C1-8, heterociclil-alquilo C1-8, heterociclil-carbonil-alquilo C1-8 o heteroaril-alquilo C1-8; donde aril-alquilo C1-8 está opcionalmente sustituido en el arilo con 1, 2, 3, 4 o 5 sustituyentes cada uno seleccionado entre hidroxi, alquilo C1-8, alcoxi C1-8, amino, alquilo C1-8-amino o alcoxicarbonilo C1-8, y donde hetrociclil-alquilo C1-8 está opcionalmente sustituido en el heterociclilo con 1, 2, 3 o 4 sustituyentes cada uno seleccionado entre hidroxi, alquilo C1-8, alcoxi C1-8, amino, alquilo C1-8-amino o alcoxicarbonilo C1-8; R2 esta selecionado de H, alquilo C1-8 o alcoxi C1-8; y R3, R4, R5, R6 y R7 está cada uno seleccionado de H, halogeno, hidroxi, alquilo C1-8, alcoxi C1-8, alcoxi C1-8-alquilo C1-8, hidroxi-alquilo C1-8, halo-alquilo C1-8, hidroxi-alcoxi C1-8, halo-alcoxi C1-8, amino, alquilo C1-8-amino, amino-alquilo C1- 8, alquilo C1-8-amino-alquilo C1-8, carboxi, acilo C1-8, alcoxicarbonilo C1-8, cicloalquilo C3-12, arilo, ariloxi, aril-alquilo C1-8, aril-alcoxi C1-8, aril-amido, heteroarilo, heteroariloxi, hteroaril-C1-8-alcoxi o heterociclilo, donde arilo, ariloxi, aril-alquilo C1-8 y aril-alcoxi C1-8 están cada uno opcionalmente sustituidos en el arilo con 1, 2, 3, 4 o 5 sustituyentes cada uno seleccionado entre ciano, halogeno, hidroxi, alquilo C1-8, alcoxi C1-8, amino, alquilo C1-8-amino, amino- alquilo C1-8, alquilo C1-8-amino-alquilo C1-8 o alcoxicarbonilo C1-8 y donde el heteroarilo y el heteroariloxi está cada uno opcionalmente sustituido en el heteroarilo con 1, 2, 3, 4 o 5 sustituyentes cada uno seleccionado entre alquilo C1-8, amino- alquilo C1-8, alquilo C1-8-amino-alquilo C1-8, carboxi C1-8 o alcoxicarbonilo C1-8.Its synthesis and use to treat, prevent or improve a chronic or acute disease, disorder or alteration mediated by protein kinases. Claim 1: A compound of formula (1) and forms thereof, wherein L is selected from a bond, C1-6 alkyl or halo- C1-6 alkyl; Ar is selected from aryl, heteroaryl, benzofused heterocyclyl or benzofused C3-12 cycloalkyl, where the benzene ring portion of the benzofused ring system is linked to the variable L; RA is selected from C = N-O-R1 or cyano; R 1 is selected from H, C 1-8 alkyl, C 1-8 alkenyl, C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl, hydroxyC 1-8 alkyl, hydroxyC 1-8 alkoxy, aminoC 1-6 alkyl 8, C1-8-amino-C1-8-alkyl, C1-8-alkoxy-C1-8-alkyl-C1-8-alkyl, C1-8-sulfonyl-C1-8-alkyl, C1-8-sulfonyloxy-alkyl C 1-8 alkyl, aryl, aryl C 1-8 alkyl, aryloxy C 1-8 alkyl, heterocyclyl C 1-8 alkyl, heterocyclyl carbonyl C 1-8 alkyl or heteroaryl C 1-8 alkyl; where aryl-C1-8 alkyl is optionally substituted in the aryl with 1, 2, 3, 4 or 5 substituents each selected from hydroxy, C1-8 alkyl, C1-8 alkoxy, amino, C1-8-amino alkyl or alkoxycarbonyl C1-8, and where hetrocyclyl-C1-8 alkyl is optionally substituted in the heterocyclyl with 1, 2, 3 or 4 substituents each selected from hydroxy, C1-8 alkyl, C1-8 alkoxy, amino, C1-8 alkyl amino or C1-8 alkoxycarbonyl; R2 is selected from H, C1-8 alkyl or C1-8 alkoxy; and R3, R4, R5, R6 and R7 are each selected from H, halogen, hydroxy, C1-8 alkyl, C1-8 alkoxy, C1-8 alkoxy-C1-8 alkyl, hydroxy-C1-8 alkyl, halo- C1-8 alkyl, hydroxy-C1-8 alkoxy, halo-C1-8 alkoxy, amino, C1-8-amino alkyl, amino-C1-8 alkyl, C1-8-amino-C1-8 alkyl, carboxy, acyl C1-8, C1-8 alkoxycarbonyl, C3-12 cycloalkyl, aryl, aryloxy, aryl-C1-8 alkyl, aryl-C1-8 alkoxy, aryl amido, heteroaryl, heteroaryloxy, heteroaryl-C1-8-alkoxy or heterocyclyl, where aryl, aryloxy, aryl-C1-8 alkyl and aryl-C1-8 alkoxy are each optionally substituted in the aryl with 1, 2, 3, 4 or 5 substituents each selected from cyano, halogen, hydroxy, C1- alkyl 8, C 1-8 alkoxy, amino, C 1-8 alkyl, amino C 1-8 alkyl, C 1-8 alkyl-C 1-8 alkyl or C 1-8 alkoxycarbonyl and where the heteroaryl and heteroaryloxy are each optionally substituted in the heteroaryl with 1, 2, 3, 4 or 5 substituents each selected from C 1-8 alkyl, amino-alkyl C1-8 yl, C1-8 alkyl-amino- C1-8 alkyl, C1-8 carboxy or C1-8 alkoxycarbonyl.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75263305P | 2005-12-21 | 2005-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058624A1 true AR058624A1 (en) | 2008-02-13 |
Family
ID=38256842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105731A AR058624A1 (en) | 2005-12-21 | 2006-12-21 | PIRIMIDINE DERIVATIVES AS INHIBITORS OF PIRIMIDIN QUINASA SUBSTITUTES. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR058624A1 (en) |
| TW (1) | TW200800919A (en) |
| WO (1) | WO2007081630A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI475996B (en) | 2007-10-19 | 2015-03-11 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| WO2009055299A1 (en) * | 2007-10-23 | 2009-04-30 | Janssen Pharmaceutica N.V. | Substituted pyrimidine-5-carboxamide and 5-carboxylic ester kinase inhibitors |
| WO2012087833A1 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Hepatitis c inhibitors and uses thereof |
| US8951993B2 (en) * | 2011-02-24 | 2015-02-10 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phosphorus containing compounds as protein kinase inhibitors |
| CA2829755A1 (en) | 2011-03-23 | 2012-09-27 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| CN103058935B (en) * | 2013-01-15 | 2015-05-06 | 四川大学 | Pyrimidine compound as well as preparation method and use for same |
| CN105073728A (en) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | Compounds and uses thereof for the modulation of hemoglobin |
| AR096654A1 (en) | 2013-06-20 | 2016-01-27 | Ab Science | DERIVATIVES OF BENZIMIDAZOL AS SELECTIVE INHIBITORS OF PROTEIN QUINASA |
| EA201992707A1 (en) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
| CN104744446B (en) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | Heteroaryl compound and its application in drug |
| US9840474B2 (en) | 2014-04-24 | 2017-12-12 | Sichuan University | Pyrimidine compounds and use as anti-cervical cancer thereof |
| BR112020021194A2 (en) | 2018-04-18 | 2021-03-23 | Constallation Pharmaceuticals, Inc. | modulators of methyl modifying enzymes, compositions and uses thereof |
| CN112262143A (en) | 2018-05-21 | 2021-01-22 | 星座制药公司 | Modulators of methyl-modified enzymes, compositions and uses thereof |
| WO2021038419A1 (en) * | 2019-08-23 | 2021-03-04 | Insilico Medicine Ip Limited | Kinase inhibitors and methods of synthesis and treatment |
| TWI750905B (en) * | 2020-11-19 | 2021-12-21 | 財團法人國家衛生研究院 | Thiazole compounds as protein kinase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| AU2002319183B2 (en) * | 2001-06-01 | 2007-05-10 | F. Hoffmann-La Roche Ag | Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| CA2451128A1 (en) * | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
-
2006
- 2006-12-12 WO PCT/US2006/061890 patent/WO2007081630A2/en active Application Filing
- 2006-12-20 TW TW095147765A patent/TW200800919A/en unknown
- 2006-12-21 AR ARP060105731A patent/AR058624A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007081630A3 (en) | 2007-12-21 |
| TW200800919A (en) | 2008-01-01 |
| WO2007081630A2 (en) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058624A1 (en) | PIRIMIDINE DERIVATIVES AS INHIBITORS OF PIRIMIDIN QUINASA SUBSTITUTES. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. | |
| AR059064A1 (en) | TIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES IN THE TREATMENT OF DISEASES MEDIATED BY PROTEIN KINASE B (PKB), SUCH AS CANCER. | |
| CL2008002131A1 (en) | Heterocycle amide compounds derived from heterocycle substituted and heterobicyclic pyrimidines, protein kinase inhibitors; pharmaceutical composition; and use of the compounds in the treatment of proliferative, neurological or neurodegenerative, cardiovascular, viral or fungal diseases. | |
| GT200600081A (en) | ACETYLENE DERIVATIVES | |
| BRPI0510170B8 (en) | compound, pharmaceutical composition for the treatment of diseases mediated by the muscarinic acetylcholine receptor and use of the compound | |
| AR094312A1 (en) | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEIVER | |
| AR056556A1 (en) | IMIDAZO (1,2-A) PIRIDINE WITH CELLULAR ANTIPROLIFERATION ACTIVITY | |
| PE20090648A1 (en) | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | |
| CL2008002295A1 (en) | Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c. | |
| EA200971143A1 (en) | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS FOR THEIR RECEIVING AND APPLICATION | |
| GT200500292A (en) | DERIVATIVES OF 2-AMIDO-4-FENILTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| CL2011000043A1 (en) | Substituted benzoazepine derived compounds; intermediate compounds; synthesis method; pharmaceutical composition; and use in the treatment or prevention of a central nervous system disorder. | |
| HN2006016313A (en) | DERIVATIVES OF REPLACED AMIDA AND METHODS OF USE | |
| CL2011002377A1 (en) | Compounds derived from fused tricyclic ring heterocyclic anthracene and biphenylene, hepatitis c virus ns5a protein inhibitors (vhc); pharmaceutical composition that includes them; and use of the compound in the preparation of a medicament useful in the treatment of hepatitis c. | |
| AR049126A1 (en) | DERIVATIVES OF 5, 6, 7, 8 - TETRAHYDROIMIDAZO [1,5A] PIRIDINE WITH INHIBITORY ACTIVITY OF ALDOSTERONE SYNTHEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF HYPERALDOSINDISM. | |
| CL2011000838A1 (en) | Heterocyclic compounds derived from ortho-condensed tetracycles with a pyrimidine 2,4,6-trione spirocondensate group, bacterial DNA gyrase inhibitors; Preparation process; pharmaceutical composition; and its use for the treatment of a bacterial infection. | |
| PE20171342A1 (en) | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | |
| CL2012002771A1 (en) | Compounds of substituted aryletinyl, modulators of mglur5 receptors; obtaining process; pharmaceutical composition; and its use in the treatment or prevention of schizophrenia, cognitive diseases, x fragile syndrome or autism. | |
| NI201100050A (en) | AMIDE DERIVATIVES OF HETEROARYLS THEIR USE AS GLUCOKINASE ACTIVATORS. | |
| CO6300954A2 (en) | DERIVATIVES OF TIENOPIRIDINONES AS PROTEIN QUINASA ACTIVATORS ACTIVATED BY AMPK | |
| PA8783501A1 (en) | DERIVATIVES OF QUINAXOLINE AS INHIBITORS OF THE TYPOSINE CINASA ACTIVITY OF THE JANUS CINASES | |
| PE20120632A1 (en) | BACE INHIBITORS | |
| AR058885A1 (en) | 3,5-SUBSTITUTED PIPERIDINE COMPOUNDS | |
| ECSP088297A (en) | 7- [2- [4- (6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL) -1-PIPERAZINIL] ETIL] -2- (1-PROPINYL) -7H-PIRAZOL- [4, 3-e] - [1,2,4] -TRIAZOL- [1,5-C] -PIRIMIDIN-5-AMINA | |
| PE20090876A1 (en) | NEW 6-ARIL / HETEROALKYLOXY BENZOTHIAZOLE AND BENZHIMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCEDURE, THEIR APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND A NEW USE MAINLY AS CMET INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |